Serviceeinschränkungen vom 12.-22.02.2026 - weitere Infos auf der UB-Homepage
American Psychological Association 6th edition

Saito, Y., Takekuma, Y., Shinagawa, N., & Sugawara, M. (2022). Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Supportive Care in Cancer, 30(5), 4081-4088. https://doi.org/10.1007/s00520-021-06757-x

ISO-690 (author-date, English)

SAITO, Yoshitaka, TAKEKUMA, Yoh, SHINAGAWA, Naofumi und SUGAWARA, Mitsuru, 2022. Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Supportive Care in Cancer. 1 Mai 2022. Vol. 30, no. 5, p. 4081-4088. DOI 10.1007/s00520-021-06757-x.

Modern Language Association 9th edition

Saito, Y., Y. Takekuma, N. Shinagawa, und M. Sugawara. „Evaluation of Risk Factors Associated With Carboplatin and Nab-Paclitaxel Treatment Suspension in Patients With Non-Small Cell Lung Cancer.“. Supportive Care in Cancer, Bd. 30, Nr. 5, Mai 2022, S. 4081-8, https://doi.org/10.1007/s00520-021-06757-x.

Mohr Siebeck - Recht (Deutsch - Österreich)

Saito, Yoshitaka/Takekuma, Yoh/Shinagawa, Naofumi/Sugawara, Mitsuru: Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer., Supportive Care in Cancer 2022, 4081-4088.

Emerald - Harvard

Saito, Y., Takekuma, Y., Shinagawa, N. und Sugawara, M. (2022), „Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer.“, Supportive Care in Cancer, Vol. 30 No. 5, S. 4081-4088.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.